<p><em>独立的克利夫兰诊所心脏评估支持 MIRACLE 2b/3 期试验推进的潜在最佳安全性特征</em></p>
<p><strong>休斯顿，2026 年 5 月 29 日（全球新闻稿）-- Moleculin Biotech, Inc.</strong>（纳斯达克：MBRX）（“Moleculin” 或 “公司”）今天宣布在 2026 年美国临床肿瘤学会（ASCO）年会上展示的新数据，进一步强化了其主要药物候选者 Annamycin（也称为 “L-Annamycin” 或 “naxtarubicin”）的差异化心脏安全特征。</p>
<p>该海报展示的题目为_“L-Annamycin 在高累积蒽环类药物暴露下的心脏安全性：汇总分析，”_ 突出了对五项已完成临床试验中评估 Annamycin 在急性髓系白血病（AML）和软组织肉瘤患者中的结果的汇总分析。该分析显示，尽管累积暴露水平大大超过传统的终生蒽环类药物剂量限制，但未检测到心脏毒性。</p>
<p>“这份海报展示为支持 Annamycin 差异化特征的临床证据增添了重要动力，” Moleculin Biotech 的董事长兼首席执行官 Walter Klemp 表示。“蒽环类药物仍然是肿瘤学中最有效的药物之一，但其长期使用历史上受到不可逆累积心脏毒性的限制。这些数据继续表明 Annamycin 可能有潜力从根本上改变这一范式。”</p>
<p>汇总分析包括 90 名在五项已完成临床试验中接受 Annamycin 治疗的患者，78 名患者提供了经过源验证的治疗前和治疗后的左心室射血分数（LVEF）评估。患者接受的 Annamycin 中位累积剂量为 660 mg/m²，暴露范围从 210 mg/m²到 2,970 mg/m²——在许多情况下，这些水平大大超过了传统蒽环类药物的终生剂量阈值。</p>
<p>分析的主要发现包括：</p>
<ul>
<li>从基线到最终评估的 LVEF 没有统计学上显著的差异（平均差异：-0.12%；95% CI，-1.34 至 1.09；p = 0.84）</li>
<li>累积 Annamycin 剂量与 LVEF 变化之间没有相关性（p= 0.12）</li>
<li>患者年龄与 LVEF 变化之间没有相关性（p=0.73）</li>
<li>对连续心电图、心脏生物标志物、心脏不良事件和可用的全球纵向应变测量的独立评审未显示药物诱导的心脏毒性证据</li>
<li>通过克利夫兰诊所心血管医学部进行的独立心脏评审</li>
</ul>
<p>重要的是，这些数据经过克利夫兰诊所心脏病专家的独立审查，为心脏安全性发现提供了额外的外部验证。</p>
<p>“在远超传统蒽环类药物限制的暴露水平下未检测到心脏毒性特别令人鼓舞，” Klemp 先生补充道。“如果在更大规模的研究中得到确认，我们相信 Annamycin 可能使患者能够继续受益于基于蒽环类药物的治疗，而无需承受与当前处方药物相关的传统累积心脏负担。”</p>
<p>该海报还强调了 Moleculin 在 1b/2 期 AML 研究中评估 Annamycin 与细胞毒药物阿糖胞苷联合使用的先前报告的疗效发现，结果显示：</p>
<ul>
<li>50% 的完全缓解（CR）率</li>
<li>60% 的复合完全缓解（CRc）率</li>
<li>意向治疗人群的中位总生存期为 12.39 个月</li>
<li>50% 的应答者能够接受潜在治愈的骨髓移植</li>
</ul>
<p>Moleculin 认为，日益增长的心脏安全性数据进一步加强了其正在进行的关键 2b/3 期 MIRACLE 试验的合理性，该试验评估 AnnAraC®（Annamycin 加阿糖胞苷）在复发或难治性 AML 中的应用。</p>
<p>蒽环类药物仍然是多种癌症类型中使用最广泛和有效的化疗药物类别之一；然而，其使用历史上受到累积剂量依赖性心脏毒性的限制。Annamycin 专门设计用于避免多药耐药机制，同时可能消除与当前处方蒽环类药物常见的心脏毒性。</p>
<p>公司的关键 2b/3 期 MIRACLE 试验仍在评估 Annamycin 在复发或难治性 AML 中的应用。该研究的前 45 名患者的解盲预计将在 2026 年 6 月进行。</p>
<p><strong>关于 Moleculin Biotech, Inc.</strong></p>
<p>Moleculin Biotech, Inc.是一家处于 3 期临床阶段的制药公司，推进一系列针对难治肿瘤和病毒的治疗候选药物。公司的主要项目 Annamycin（也称为 naxtarubicin）是一种新一代高效且耐受性良好的蒽环类药物，旨在避免多药耐药机制，并缺乏与当前处方蒽环类药物相关的心脏毒性。Annamycin 目前正在开发用于治疗复发或难治性急性髓系白血病（AML）和软组织肉瘤（STS）肺转移。</p>
<p>公司已开始 MIRACLE（<strong>M</strong>olecul <strong>i</strong>n <strong>R</strong>/R AML <strong>A</strong>nnAraC <strong>Cl</strong> inical <strong>E</strong>valuation）试验（MB-108），这是一项关键的、适应性设计的 2b/3 期试验，评估 Annamycin 与阿糖胞苷联合使用，统称为 AnnAraC（Annamycin 与阿糖胞苷的组合，也称为 “Ara-C”），用于治疗复发或难治性急性髓系白血病。在成功的 1B/2 期研究（MB-106）后，在 FDA 的指导下，公司相信它已大大降低了 Annamycin 治疗 AML 的潜在批准路径的风险。该研究仍需适当的未来申请，并可能获得 FDA 及其外国等效机构的额外反馈。</p>
<p>此外，公司正在开发 WP1066，这是一种免疫/转录调节剂，能够抑制 p-STAT3 和其他致癌转录因子，同时刺激自然免疫反应，针对脑肿瘤、胰腺癌和其他癌症。Moleculin 的产品线中还有一系列抗代谢物，包括 WP1122，旨在潜在治疗病原病毒以及某些癌症适应症。</p>
<p>有关公司的更多信息，请访问 www.moleculin.com，并在 X、LinkedIn 和 Facebook 上与我们联系。</p>
<p><strong>前瞻性声明</strong></p>
<p>本公告中的某些声明属于 1933 年证券法第 27A 条、1934 年证券交易法第 21E 条和 1995 年私人证券诉讼改革法的前瞻性声明，涉及风险和不确定性。本新闻稿中的前瞻性声明包括但不限于 Annamycin 和 AnnAraC 在复发/难治性急性髓性白血病（R/R AML）及其他适应症中的潜在疗效和安全性，Annamycin 在不受心脏毒性相关的累积剂量限制的情况下提供有效的蒽环类药物治疗的潜力，以及临床试验里程碑的预期时间，包括初始患者数据的解盲。Moleculin 将需要大量额外融资，而公司尚未获得相关承诺，以进行本新闻稿中描述的临床试验，并且本新闻稿中描述的里程碑假设公司能够及时获得此类融资。尽管 Moleculin 相信这些前瞻性声明所反映的预期在作出时是合理的，但这些预期可能与前瞻性声明所表达或暗示的结果存在重大差异。公司依赖其专家的报告，以确认心脏毒性的缺失。本新闻稿中提到的数据集需经过对当前和未来临床试验中未来受试者数据的审查，以及对当前试验中受试者的长期跟踪。Moleculin 试图通过包括 “相信”、“估计”、“预期”、“期待”、“计划”、“项目”、“打算”、“潜在”、“可能”、“可以”、“会”、“应该”、“大约” 或其他传达未来事件或结果不确定性的词汇来识别前瞻性声明。这些声明仅为预测，涉及已知和未知的风险、不确定性和其他因素，包括在我们最近提交给证券交易委员会（SEC）的 10-K 表格中的第 1A 项 “风险因素” 下讨论的因素，并在我们提交的 10-Q 表格和其他公开文件中不时更新。本公告中包含的任何前瞻性声明仅在其日期时有效。我们没有义务更新本公告中包含的任何前瞻性声明，以反映其日期之后发生的事件或情况，或反映意外事件的发生。</p>
<p><strong>投资者联系：</strong></p>
<p>JTC Team, LLC</p>
<p>Jenene Thomas</p>
<p>(908) 824-0775</p>
<p>MBRX@jtcir.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU9EVXlNaU0zTmpJMk9EVXdJelV3TURFek16WXdOdz09?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU9EVXlNaU0zTmpJMk9EVXdJelV3TURFek16WXdOdz09"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDhkNjZjMDUtMTJhNi00Y2VkLThhMzAtY2RmYWU5YzgyYjlhLTUwMDEzMzYwNy0yMDI2LTA1LTI5LWVu/tiny/Moleculin-Biotech-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDhkNjZjMDUtMTJhNi00Y2VkLThhMzAtY2RmYWU5YzgyYjlhLTUwMDEzMzYwNy0yMDI2LTA1LTI5LWVu/tiny/Moleculin-Biotech-Inc-.png"/></p>

MBRX

标普生物技术 ETF - SPDR

标普生物技术 3 倍做多 - Direxion

<p>Moleculin Biotech 提交了 2026 年 ASCO 数据，显示 Annamycin 在暴露水平远超传统蒽环类药物限制的情况下没有可检测的心脏毒性。克利夫兰诊所的独立审查在对 90 名患者的汇总分析中支持了这些安全性发现。该公司强调，这一独特的心脏特征增强了其正在进行的 2b/3 期 MIRACLE 试验的合理性，该试验针对复发/难治性急性髓系白血病，预计将在 2026 年 6 月解盲</p>

<p><em>Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances</em></p>
<div class="lb-trans"><p><em>独立的克利夫兰诊所心脏评估支持 MIRACLE 2b/3 期试验推进的潜在最佳安全性特征</em></p>
</div><p><strong>HOUSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.</strong>, (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced new data presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting further reinforcing the differentiated cardiac safety profile of its lead drug candidate, Annamycin (also known as “L-Annamycin” or “naxtarubicin”).</p>
<div class="lb-trans"><p><strong>休斯顿，2026 年 5 月 29 日（全球新闻稿）-- Moleculin Biotech, Inc.</strong>（纳斯达克：MBRX）（“Moleculin” 或 “公司”）今天宣布在 2026 年美国临床肿瘤学会（ASCO）年会上展示的新数据，进一步强化了其主要药物候选者 Annamycin（也称为 “L-Annamycin” 或 “naxtarubicin”）的差异化心脏安全特征。</p>
</div><p>The poster presentation, titled <em>“Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis,”</em> highlighted findings from a pooled analysis across five completed clinical trials evaluating Annamycin in patients with acute myeloid leukemia (AML) and soft tissue sarcoma. The analysis demonstrated no detectable cardiotoxicity despite cumulative exposure levels that substantially exceeded traditional lifetime anthracycline dose limitations.</p>
<div class="lb-trans"><p>该海报展示的题目为_“L-Annamycin 在高累积蒽环类药物暴露下的心脏安全性：汇总分析，”_ 突出了对五项已完成临床试验中评估 Annamycin 在急性髓系白血病（AML）和软组织肉瘤患者中的结果的汇总分析。该分析显示，尽管累积暴露水平大大超过传统的终生蒽环类药物剂量限制，但未检测到心脏毒性。</p>
</div><p>“This poster presentation adds significant momentum to the growing clinical evidence supporting Annamycin’s differentiated profile,” said Walter Klemp, Chairman and CEO of Moleculin Biotech. “Anthracyclines remain among the most effective agents in oncology, yet their long-term use has historically been constrained by irreversible cumulative cardiotoxicity. These data continue to suggest that Annamycin may have the potential to fundamentally change that paradigm.”</p>
<div class="lb-trans"><p>“这份海报展示为支持 Annamycin 差异化特征的临床证据增添了重要动力，” Moleculin Biotech 的董事长兼首席执行官 Walter Klemp 表示。“蒽环类药物仍然是肿瘤学中最有效的药物之一，但其长期使用历史上受到不可逆累积心脏毒性的限制。这些数据继续表明 Annamycin 可能有潜力从根本上改变这一范式。”</p>
</div><p>The pooled analysis included 90 patients treated with Annamycin across five completed clinical trials, with source-verified paired pre- and post-treatment left ventricular ejection fraction (LVEF) assessments available for 78 patients. Patients received a median cumulative Annamycin dose of 660 mg/m², with exposure ranging from 210 mg/m² to 2,970 mg/m² — levels that, in many cases, substantially exceeded conventional anthracycline lifetime dose thresholds.</p>
<div class="lb-trans"><p>汇总分析包括 90 名在五项已完成临床试验中接受 Annamycin 治疗的患者，78 名患者提供了经过源验证的治疗前和治疗后的左心室射血分数（LVEF）评估。患者接受的 Annamycin 中位累积剂量为 660 mg/m²，暴露范围从 210 mg/m²到 2,970 mg/m²——在许多情况下，这些水平大大超过了传统蒽环类药物的终生剂量阈值。</p>
</div><p>Key findings from the analysis included:</p>
<div class="lb-trans"><p>分析的主要发现包括：</p>
</div><ul>
<li>No statistically significant difference in LVEF from baseline to final assessment (mean difference: -0.12%; 95% CI, -1.34 to 1.09; p = 0.84)</li>
<li>No correlation between cumulative Annamycin dose and change in LVEF (p= 0.12)</li>
<li>No correlation between patient age and change in LVEF (p=0.73)</li>
<li>Independent review of serial ECGs, cardiac biomarkers, cardiac adverse events and available global longitudinal strain measurements demonstrated no evidence of drug-induced cardiotoxicity</li>
<li>Independent cardiac review conducted through the Cleveland Clinic Division of Cardiovascular Medicine</li>
</ul>
<div class="lb-trans"><ul>
<li>从基线到最终评估的 LVEF 没有统计学上显著的差异（平均差异：-0.12%；95% CI，-1.34 至 1.09；p = 0.84）</li>
<li>累积 Annamycin 剂量与 LVEF 变化之间没有相关性（p= 0.12）</li>
<li>患者年龄与 LVEF 变化之间没有相关性（p=0.73）</li>
<li>对连续心电图、心脏生物标志物、心脏不良事件和可用的全球纵向应变测量的独立评审未显示药物诱导的心脏毒性证据</li>
<li>通过克利夫兰诊所心血管医学部进行的独立心脏评审</li>
</ul>
</div><p>Importantly, the data were independently reviewed by Cleveland Clinic cardiology specialists, providing additional external validation to the cardiac safety findings.</p>
<div class="lb-trans"><p>重要的是，这些数据经过克利夫兰诊所心脏病专家的独立审查，为心脏安全性发现提供了额外的外部验证。</p>
</div><p>“The absence of detectable cardiotoxicity at exposure levels well beyond conventional anthracycline limits is particularly encouraging,” added Mr. Klemp. “If confirmed in larger studies, we believe Annamycin could potentially enable patients to continue benefiting from anthracycline-based therapy without the traditional cumulative cardiac burden associated with currently prescribed agents.”</p>
<div class="lb-trans"><p>“在远超传统蒽环类药物限制的暴露水平下未检测到心脏毒性特别令人鼓舞，” Klemp 先生补充道。“如果在更大规模的研究中得到确认，我们相信 Annamycin 可能使患者能够继续受益于基于蒽环类药物的治疗，而无需承受与当前处方药物相关的传统累积心脏负担。”</p>
</div><p>The poster also highlighted previously reported efficacy findings from Moleculin’s Phase 1b/2 AML study evaluating Annamycin in combination with cytarabine, which demonstrated:</p>
<div class="lb-trans"><p>该海报还强调了 Moleculin 在 1b/2 期 AML 研究中评估 Annamycin 与细胞毒药物阿糖胞苷联合使用的先前报告的疗效发现，结果显示：</p>
</div><ul>
<li>50% complete remission (CR) rate</li>
<li>60% composite complete remission (CRc) rate</li>
<li>Median overall survival of 12.39 months in the intent-to-treat population</li>
<li>50% of responders were able to receive a potentially curative bone marrow transplant</li>
</ul>
<div class="lb-trans"><ul>
<li>50% 的完全缓解（CR）率</li>
<li>60% 的复合完全缓解（CRc）率</li>
<li>意向治疗人群的中位总生存期为 12.39 个月</li>
<li>50% 的应答者能够接受潜在治愈的骨髓移植</li>
</ul>
</div><p>Moleculin believes the growing body of cardiac safety data further strengthens the rationale for its ongoing pivotal Phase 2b/3 MIRACLE trial evaluating AnnAraC® (Annamycin plus cytarabine) in relapsed or refractory AML.</p>
<div class="lb-trans"><p>Moleculin 认为，日益增长的心脏安全性数据进一步加强了其正在进行的关键 2b/3 期 MIRACLE 试验的合理性，该试验评估 AnnAraC®（Annamycin 加阿糖胞苷）在复发或难治性 AML 中的应用。</p>
</div><p>Anthracyclines remain one of the most widely used and effective classes of chemotherapy agents across multiple cancer types; however, their use has historically been limited by cumulative dose-dependent cardiotoxicity. Annamycin was specifically designed to avoid multidrug resistance mechanisms while potentially eliminating the cardiotoxicity commonly associated with currently prescribed anthracyclines.</p>
<div class="lb-trans"><p>蒽环类药物仍然是多种癌症类型中使用最广泛和有效的化疗药物类别之一；然而，其使用历史上受到累积剂量依赖性心脏毒性的限制。Annamycin 专门设计用于避免多药耐药机制，同时可能消除与当前处方蒽环类药物常见的心脏毒性。</p>
</div><p>The Company’s ongoing pivotal Phase 2b/3 MIRACLE trial continues to evaluate Annamycin in relapsed or refractory AML. Unblinding from the first 45 patients from this study is on track for June 2026.</p>
<div class="lb-trans"><p>公司的关键 2b/3 期 MIRACLE 试验仍在评估 Annamycin 在复发或难治性 AML 中的应用。该研究的前 45 名患者的解盲预计将在 2026 年 6 月进行。</p>
</div><p><strong>About Moleculin Biotech, Inc.</strong></p>
<div class="lb-trans"><p><strong>关于 Moleculin Biotech, Inc.</strong></p>
</div><p>Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a next-generation highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.</p>
<div class="lb-trans"><p>Moleculin Biotech, Inc.是一家处于 3 期临床阶段的制药公司，推进一系列针对难治肿瘤和病毒的治疗候选药物。公司的主要项目 Annamycin（也称为 naxtarubicin）是一种新一代高效且耐受性良好的蒽环类药物，旨在避免多药耐药机制，并缺乏与当前处方蒽环类药物相关的心脏毒性。Annamycin 目前正在开发用于治疗复发或难治性急性髓系白血病（AML）和软组织肉瘤（STS）肺转移。</p>
</div><p>The Company has begun the MIRACLE ( <strong>M</strong> olecul <strong>i</strong> n <strong>R</strong>/R AML <strong>A</strong> nnAraC <strong>Cl</strong> inical <strong>E</strong> valuation) Trial (MB-108), a pivotal, adaptive design Phase 2b/3 trial evaluating Annamycin in combination with cytarabine, together referred to as AnnAraC (the combination of Annamycin and cytarabine, also referred to as “Ara-C”) for the treatment of relapsed or refractory acute myeloid leukemia. Following a successful Phase 1B/2 study (MB-106), with input from the FDA, the Company believes it has substantially de-risked the development pathway towards a potential approval for Annamycin for the treatment of AML. This study remains subject to appropriate future filings with potential additional feedback from the FDA and their foreign equivalents.</p>
<div class="lb-trans"><p>公司已开始 MIRACLE（<strong>M</strong>olecul <strong>i</strong>n <strong>R</strong>/R AML <strong>A</strong>nnAraC <strong>Cl</strong> inical <strong>E</strong>valuation）试验（MB-108），这是一项关键的、适应性设计的 2b/3 期试验，评估 Annamycin 与阿糖胞苷联合使用，统称为 AnnAraC（Annamycin 与阿糖胞苷的组合，也称为 “Ara-C”），用于治疗复发或难治性急性髓系白血病。在成功的 1B/2 期研究（MB-106）后，在 FDA 的指导下，公司相信它已大大降低了 Annamycin 治疗 AML 的潜在批准路径的风险。该研究仍需适当的未来申请，并可能获得 FDA 及其外国等效机构的额外反馈。</p>
</div><p>Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin also has in its pipeline a portfolio of antimetabolites, including WP1122 for the potential treatment of pathogenic viruses, as well as certain cancer indications.</p>
<div class="lb-trans"><p>此外，公司正在开发 WP1066，这是一种免疫/转录调节剂，能够抑制 p-STAT3 和其他致癌转录因子，同时刺激自然免疫反应，针对脑肿瘤、胰腺癌和其他癌症。Moleculin 的产品线中还有一系列抗代谢物，包括 WP1122，旨在潜在治疗病原病毒以及某些癌症适应症。</p>
</div><p>For more information about the Company, please visit www.moleculin.com and connect on X, LinkedIn and Facebook.</p>
<div class="lb-trans"><p>有关公司的更多信息，请访问 www.moleculin.com，并在 X、LinkedIn 和 Facebook 上与我们联系。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential efficacy and safety of Annamycin and AnnAraC in R/R AML and other indications, the potential for Annamycin to provide effective anthracycline therapy without cumulative dose limitations associated with cardiotoxicity, and the anticipated timing of clinical trial milestones including unblinding of initial patient data. Moleculin will require significant additional financing, for which the Company has no commitments, in order to conduct its clinical trials as described in this press release, and the milestones described in this press release assume the Company’s ability to secure such financing on a timely basis. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company relies on the reports of its expert with regard to the absence of cardiotoxicity. The dataset referenced in this press release is subject to the review of the data from future subjects in its current and future clinical trials and long-term follow-up with subjects in its current trials. Moleculin has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.</p>
<div class="lb-trans"><p>本公告中的某些声明属于 1933 年证券法第 27A 条、1934 年证券交易法第 21E 条和 1995 年私人证券诉讼改革法的前瞻性声明，涉及风险和不确定性。本新闻稿中的前瞻性声明包括但不限于 Annamycin 和 AnnAraC 在复发/难治性急性髓性白血病（R/R AML）及其他适应症中的潜在疗效和安全性，Annamycin 在不受心脏毒性相关的累积剂量限制的情况下提供有效的蒽环类药物治疗的潜力，以及临床试验里程碑的预期时间，包括初始患者数据的解盲。Moleculin 将需要大量额外融资，而公司尚未获得相关承诺，以进行本新闻稿中描述的临床试验，并且本新闻稿中描述的里程碑假设公司能够及时获得此类融资。尽管 Moleculin 相信这些前瞻性声明所反映的预期在作出时是合理的，但这些预期可能与前瞻性声明所表达或暗示的结果存在重大差异。公司依赖其专家的报告，以确认心脏毒性的缺失。本新闻稿中提到的数据集需经过对当前和未来临床试验中未来受试者数据的审查，以及对当前试验中受试者的长期跟踪。Moleculin 试图通过包括 “相信”、“估计”、“预期”、“期待”、“计划”、“项目”、“打算”、“潜在”、“可能”、“可以”、“会”、“应该”、“大约” 或其他传达未来事件或结果不确定性的词汇来识别前瞻性声明。这些声明仅为预测，涉及已知和未知的风险、不确定性和其他因素，包括在我们最近提交给证券交易委员会（SEC）的 10-K 表格中的第 1A 项 “风险因素” 下讨论的因素，并在我们提交的 10-Q 表格和其他公开文件中不时更新。本公告中包含的任何前瞻性声明仅在其日期时有效。我们没有义务更新本公告中包含的任何前瞻性声明，以反映其日期之后发生的事件或情况，或反映意外事件的发生。</p>
</div><p><strong>Investor Contact:</strong></p>
<div class="lb-trans"><p><strong>投资者联系：</strong></p>
</div><p>JTC Team, LLC</p>
<div class="lb-trans"><p>JTC Team, LLC</p>
</div><p>Jenene Thomas</p>
<div class="lb-trans"><p>Jenene Thomas</p>
</div><p>(908) 824-0775</p>
<div class="lb-trans"><p>(908) 824-0775</p>
</div><p>MBRX@jtcir.com</p>
<div class="lb-trans"><p>MBRX@jtcir.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeU9EVXlNaU0zTmpJMk9EVXdJelV3TURFek16WXdOdz09" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcyODUyMiM3NjI2ODUwIzUwMDEzMzYwNw=="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ZDhkNjZjMDUtMTJhNi00Y2VkLThhMzAtY2RmYWU5YzgyYjlhLTUwMDEzMzYwNy0yMDI2LTA1LTI5LWVu/tiny/Moleculin-Biotech-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/ZDhkNjZjMDUtMTJhNi00Y2VkLThhMzAtY2RmYWU5YzgyYjlhLTUwMDEzMzYwNy0yMDI2LTA1LTI5LWVu/tiny/Moleculin-Biotech-Inc-.png"/></p>

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits | MBRX Stock News

StockTitan

Moleculin Biotech

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做空 - Direxion

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做空纳斯达克生物技术 ETF - ProShares

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

Moleculin 展示 ASCO 2026 数据，表明尽管 Annamycin 的暴露水平远远超过传统蒽环类药物的限制，但未检测到心脏毒性 | Moleculin Biotech 股票新闻